摘要
目的:探讨注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合柳氮磺吡啶治疗强直性脊柱炎的临床效果。方法:选取2012年1月—2014年1月期间来大连市第二人民医院(以下简称"我院")就诊的强直性脊柱炎患者100例,按照随机数字表法分为对照组和观察组各50例。对照组患者使用柳氮磺吡啶治疗;观察组患者使用注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合柳氮磺吡啶治疗,3个月为1个疗程。结果:经过1个疗程的治疗,2组患者强直性脊柱炎病情活动指数(BASDAI)评分、关节肿胀程度、晨僵时间、红细胞沉降率(ESR)、C反应蛋白水平(CRP)均有所下降。观察组患者临床缓解情况优于对照组,2组差异有统计学意义(P<0.05);观察组总有效率为94%(47/50),高于对照组的70%(35/50),2组差异有统计学意义(P<0.05)。结论:注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合柳氮磺吡啶治疗强直性脊柱炎,临床效果良好,值得临床推广。
OBJECTIVE：To explore the clinical efficacy of recombinant human interferon type Ⅱ tumor necrosis factor receptors plus sulfasalazine for ankylosing spondylitis. METHODS：100 patients with ankylosing spondylitis in our hospital from January 2012 to January 2014 were randomly divided into control group and experimental group, with control group given sulfasalazine alone and the experimental group given etanercept plus sulfasalazine for 3 months（ a＆nbsp;course of treatment ） . RESULTS： After treatment of one course, both groups showed reduction in BASDAI score, degree of joint swelling, duration of morning stiffness, erythrocyte sedimentation rate and C-reactive protein;however, the patients in the experimental group showed better clinical remission than in the control group and the difference between the two groups was significant（P〈0.05）; the total effective rate in the experimental group was significantly higher than in the control group [ 94%（ 47/50 ） vs. 70%（ 35/50 ） ] and the difference between the two groups was significant （ P 〈0.05 ） . CONCLUSIONS： Etanercept plus sulfasalazine showed remarkable efficacy for ankylosing spondylitis, which thus is worthy of popularization in clinical application.
出处
《中国医院用药评价与分析》
2014年第12期1083-1085,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
